Scilex Holding (SCLX) Asset Writedowns and Impairment (2024)
Scilex Holding (SCLX) recorded quarterly Asset Writedowns and Impairment of $14.8 million in Q4 2024, up 1183.32% quarter-over-quarter from $1.2 million in Q2 2024.
Scilex Holding (SCLX) Asset Writedowns and Impairment (2024) Analysis & Trends
Scilex Holding's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $14.8 million for Q4 2024.
- In Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM figure through Dec 2024 stood at $17.3 million (changed N/A YoY), while the FY2024 annual figure was $17.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $14.8 million for Q4 2024 at Scilex Holding, up from $1.2 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $14.8 million in Q4 2024 to a low of $1.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.77 Mn |
| Dec 31, 2024 | 14.77 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |